Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms
Copyright ©The authors 2023..
BACKGROUND: Autoimmunity has been reported in patients with severe coronavirus disease 2019 (COVID-19). We investigated whether anti-nuclear/extractable-nuclear antibodies (ANAs/ENAs) were present up to a year after infection, and if they were associated with the development of clinically relevant post-acute sequalae of COVID-19 (PASC) symptoms.
METHODS: A rapid-assessment line immunoassay was used to measure circulating levels of ANAs/ENAs in 106 convalescent COVID-19 patients with varying acute phase severities at 3, 6 and 12 months post-recovery. Patient-reported fatigue, cough and dyspnoea were recorded at each time point. Multivariable logistic regression model and receiver operating curves were used to test the association of autoantibodies with patient-reported outcomes and pro-inflammatory cytokines.
RESULTS: Compared to age- and sex-matched healthy controls (n=22) and those who had other respiratory infections (n=34), patients with COVID-19 had higher detectable ANAs at 3 months post-recovery (p<0.001). The mean number of ANA autoreactivities per individual decreased between 3 and 12 months (from 3.99 to 1.55) with persistent positive titres associated with fatigue, dyspnoea and cough severity. Antibodies to U1-snRNP and anti-SS-B/La were both positively associated with persistent symptoms of fatigue (p<0.028, area under the curve (AUC) 0.86) and dyspnoea (p<0.003, AUC=0.81). Pro-inflammatory cytokines such as tumour necrosis factor (TNF)-α and C-reactive protein predicted the elevated ANAs at 12 months. TNF-α, D-dimer and interleukin-1β had the strongest association with symptoms at 12 months. Regression analysis showed that TNF-α predicted fatigue (β=4.65, p=0.004) and general symptomaticity (β=2.40, p=0.03) at 12 months.
INTERPRETATION: Persistently positive ANAs at 12 months post-COVID are associated with persisting symptoms and inflammation (TNF-α) in a subset of COVID-19 survivors. This finding indicates the need for further investigation into the role of autoimmunity in PASC.
| Errataetall: |
CommentIn: Eur Respir J. 2023 Jan 12;61(1):. - PMID 36634924 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
The European respiratory journal - 61(2023), 1 vom: 22. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Son, Kiho [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Antinuclear |
|---|
| Anmerkungen: |
Date Completed 16.01.2023 Date Revised 23.03.2023 published: Electronic-Print CommentIn: Eur Respir J. 2023 Jan 12;61(1):. - PMID 36634924 Citation Status MEDLINE |
|---|
| doi: |
10.1183/13993003.00970-2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34653965X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34653965X | ||
| 003 | DE-627 | ||
| 005 | 20231226031714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.00970-2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM34653965X | ||
| 035 | |a (NLM)36137590 | ||
| 035 | |a (PII)2200970 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Son, Kiho |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2023 | ||
| 500 | |a Date Revised 23.03.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentIn: Eur Respir J. 2023 Jan 12;61(1):. - PMID 36634924 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright ©The authors 2023. | ||
| 520 | |a BACKGROUND: Autoimmunity has been reported in patients with severe coronavirus disease 2019 (COVID-19). We investigated whether anti-nuclear/extractable-nuclear antibodies (ANAs/ENAs) were present up to a year after infection, and if they were associated with the development of clinically relevant post-acute sequalae of COVID-19 (PASC) symptoms | ||
| 520 | |a METHODS: A rapid-assessment line immunoassay was used to measure circulating levels of ANAs/ENAs in 106 convalescent COVID-19 patients with varying acute phase severities at 3, 6 and 12 months post-recovery. Patient-reported fatigue, cough and dyspnoea were recorded at each time point. Multivariable logistic regression model and receiver operating curves were used to test the association of autoantibodies with patient-reported outcomes and pro-inflammatory cytokines | ||
| 520 | |a RESULTS: Compared to age- and sex-matched healthy controls (n=22) and those who had other respiratory infections (n=34), patients with COVID-19 had higher detectable ANAs at 3 months post-recovery (p<0.001). The mean number of ANA autoreactivities per individual decreased between 3 and 12 months (from 3.99 to 1.55) with persistent positive titres associated with fatigue, dyspnoea and cough severity. Antibodies to U1-snRNP and anti-SS-B/La were both positively associated with persistent symptoms of fatigue (p<0.028, area under the curve (AUC) 0.86) and dyspnoea (p<0.003, AUC=0.81). Pro-inflammatory cytokines such as tumour necrosis factor (TNF)-α and C-reactive protein predicted the elevated ANAs at 12 months. TNF-α, D-dimer and interleukin-1β had the strongest association with symptoms at 12 months. Regression analysis showed that TNF-α predicted fatigue (β=4.65, p=0.004) and general symptomaticity (β=2.40, p=0.03) at 12 months | ||
| 520 | |a INTERPRETATION: Persistently positive ANAs at 12 months post-COVID are associated with persisting symptoms and inflammation (TNF-α) in a subset of COVID-19 survivors. This finding indicates the need for further investigation into the role of autoimmunity in PASC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Antibodies, Antinuclear |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Jamil, Rameen |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Abhiroop |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Manan |e verfasserin |4 aut | |
| 700 | 1 | |a Venegas, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Miyasaki, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kayla |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Zil |e verfasserin |4 aut | |
| 700 | 1 | |a Salter, Brittany |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Agnes Che Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Kevin Soon-Keen |e verfasserin |4 aut | |
| 700 | 1 | |a Cowbrough, Braeden |e verfasserin |4 aut | |
| 700 | 1 | |a Radford, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chynna |e verfasserin |4 aut | |
| 700 | 1 | |a Kjarsgaard, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Dvorkin-Gheva, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, James |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Quan-Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Waserman, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Ryerson, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Parameswaran |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Terence |e verfasserin |4 aut | |
| 700 | 1 | |a Balakrishnan, Narayanaswamy |e verfasserin |4 aut | |
| 700 | 1 | |a Nazy, Ishac |e verfasserin |4 aut | |
| 700 | 1 | |a Bowdish, Dawn M E |e verfasserin |4 aut | |
| 700 | 1 | |a Svenningsen, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Carlsten, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Manali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g 61(2023), 1 vom: 22. Jan. |w (DE-627)NLM012664782 |x 0903-1936 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:1 |g day:22 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.00970-2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 1 |b 22 |c 01 | ||